Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Part of paid clinical trials in Aurora, Colorado.

Sponsor
University of Colorado, Denver
Study ID
NCT03042221
Status
Recruiting
Apply to this trial

Conditions

  • ALK Gene Mutation
  • BRAF V600E
  • EGFR Gene Mutation
  • Non-Small Cell Carcinoma of Lung, TNM Stage 4
  • Non-Small Cell Lung Cancer
  • ROSE Cluster 1

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Study Details

A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes.

Key Dates

Start date
May 10, 2016
Status verified
Feb 2026
Primary completion
Nov 1, 2026
Completion
Sep 30, 2027

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

gene expression changes [ Time Frame: baseline and 2 weeks (+/- 1 week) for each patient. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Colorado, Cancer CenterAuroraColorado80045
Brandi Kubala
[email protected]
303-724-1657
Erin Schenk
[email protected]
303-724-4304
Erin Schenk (PRINCIPAL_INVESTIGATOR)

Find similar trials in Aurora, CO

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Colorado, Cancer Center· Aurora, CO

Related Studies